Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

Table 1

Baseline characteristics of the included studies.

Study	Regimen	Duration (weeks)	Genotype	n	Age (mean)	Male (%)	Prior HCV treatment (%)		Cirrhosis (%)	Viral load
							Naïve	Experienced		HCV RNA log10 IU/mL (mean)	HCV RNA ≥ 800,000 IU/mL (%)
Lawitz et al. [29]	SOF + PR	12	5	1	—	—	100	0	—	—	—
	SOF + PR	12	6	6	—	—	100	0	—	—	—
Kowdley et al. [27]	SOF + PR	24	6	5	—	—	100	0	0	-	—
Gane et al. [24]	SOF/LDV	12	6	25	51	64	92	8	8	6.7	—
Curry et al. [21]	SOF/VEL	24	6	1	67	100	100	0	100	6.5	100
Everson et al. [22]	SOF/VEL	12	6	5	54	80	100	0	0	6.7	80
	SOF/VEL	12	6	4	57	100	25	75	100
	25 mg									6.1	75
Feld et al. [23]	SOF/VEL	12	5	35	—	—	—	—	—	—	—
	SOF/VEL	12	6	41	—	—	—	—	—	—	—
Gane et al. [25]	SOF/VEL/VOX	8	6	1	—	—	100	0	100	—	—
	SOF/VEL/VOX	12	6	2	—	—	0	100	50	—	—
Abergel et al. [20]	SOF/LDV	12	5	41	—	51	51	49	22	—	—
Lai et al. [28]	SOF + RBV	12	6	3	—	—	100	0	—	—	—
	SOF + RBV	16	6	4	—	—	100	0	—	—	—
	SOF + RBV	24	6	4	—	—	100	0	—	—	—
Jacobson et al. [26]	SOF/VEL/VOX	8	5	18	—	—	—	—	—	—	—
	SOF/VEL/VOX	8	6	30	—	—	—	—	—	—	—
	SOF/VEL	12	6	9	—	—	—	—	—	—	—
Nguyen et al. [30]	SOF/LDV	8	6	20	57	55	100	0	0	6.2	—
	SOF/LDV	12	6	40	59	60	62	38	68	6.6	—
Wei et al. [32]	SOF + PR	12	6	32	38	47	69	31	6	6.5	84
	SOF + RBV	24	6	4	36	75	50	50	0	6.4	50
Thuy et al. [31]	SOF/LDV	12	6	86	52	47	92	8	2	6.7	63
	SOF/LDV + RBV	12	6	39	59	39	33	67	56	6.7	85
	SOF/LDV	24	6	20	63	30	65	35	90	6.5	70
	SOF/LDV + RBV	24	6	30	64	40	70	30	97	6.7	82

SOF, sofosbuvir; VEL, velpatasvir; LDV, ledipasvir; VOX, voxilaprevir; PR, PegIFN + ribavirin; RBV, ribavirin. Standard dose of each drug is as follows: SOF, 400 mg per day; VEL, 100 mg per day; LDV, 90 mg per day; VOX, 100 mg per day; PegIFN 180 μg per week; RBV 1000–1200 mg per day. Standard dose of VEL is 100 mg per day. In this study (Everson 2005), a VEL dose of 25 mg per day was experimented.